SEC Form 4 · accession 0001144204-17-012940
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ralph Dr. Kern
Officer — COO and Chief Medical Officer
Period of report
Mar 6, 2017
Accepted (ET)
Mar 6, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 6, 2017 | A | 35,885 | $0.00 | A | 35,885 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $4.18 | Mar 6, 2017 | A | 47,847 | A | Mar 6, 2017 | Mar 6, 2019 | Common Stock | 47,847 | 47,847 | D |
Explanation of responses
- F1Shares acquired are shares of restricted stock awarded on March 6, 2017 under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock vest as to 25% of the award on each of the first, second, third and fourth anniversary of the date of grant, provided that the Reporting Person remains continuously employed by the Company from the date of grant through each applicable vesting date.
- F2Option is fully vested and exercisable as of the date of grant and shall remain exercisable until the 2nd anniversary of the date of grant.